Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)

Conference paper

Morgensztern D. et al, (2018), JOURNAL OF THORACIC ONCOLOGY, 13, S489 - S489

Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma

Conference paper

Fennell D. et al, (2018), JOURNAL OF THORACIC ONCOLOGY, 13, S397 - S397

Quality of Life in Patients with Advanced NSCLC Treated in Second-or Third-Line with Nab-Paclitaxel plus Durvalumab: ABOUND. 2L+

Conference paper

Talbot D. et al, (2018), JOURNAL OF THORACIC ONCOLOGY, 13, S498 - S499

Primary Ovarian Carcinoid: Extensive Clinical Experience With an Underrecognized Uncommon Entity.

Journal article

Preda VA. et al, (2018), Int J Gynecol Cancer, 28, 466 - 471

1-Year Survival Rates for Neuroendocrine Tumor Patients in England

Conference paper

Genus T. et al, (2018), NEUROENDOCRINOLOGY, 106, 83 - 83

Incidence and Prevalence of Neuroendocrine Tumors in England

Conference paper

Genus T. et al, (2018), NEUROENDOCRINOLOGY, 106, 84 - 84

Metachronous Primary Cancers in Neuroendocrine Tumor Patients

Conference paper

Genus T. et al, (2018), NEUROENDOCRINOLOGY, 106, 85 - 85

Nab-Paclitaxel plus Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+

Conference paper

Govindan R. et al, (2017), JOURNAL OF THORACIC ONCOLOGY, 12, S1839 - S1840

Load More